Top Markets
#1 MowCat MowCat +48.96%
#2 Bermuda Shorts Bermuda Shorts +30.38%
#3 Velvet Velvet +25.38%
#4 Audiera Audiera +22.91%
#5 aPriori aPriori +21.24%
#6 Derive Derive +21.04%
#7 Quack AI Quack AI +19.37%
#8 Biconomy Biconomy +16.01%
#9 Perle Perle +12.23%
#10 Geodnet Geodnet +11.94%
Coin of the day
MowCat MowCat
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
AzurRx BioPharma, Inc. AzurRx BioPharma, Inc.

AzurRx BioPharma, Inc.

AZRX
Kedudukan dalam Saham #35193
AzurRx BioPharma, Inc., a Brooklyn, New York-based company employing 12... AzurRx BioPharma, Inc., a Brooklyn, New York-based company employing 12 full-time individuals, focuses on the discovery and advancement of non-systemic biological treatments for various gastrointestinal conditions. Its current developmental portfolio comprises two therapeutic protein assets: MS1819 and AZX1101. MS1819 is an acid-stable lipase enzyme (LIP2), originating from Yarrowia lipolytica, which AzurRx is genetically engineering to address exocrine pancreatic insufficiency (EPI). EPI is a debilitating disorder often seen in patients with chronic pancreatitis (CP) and cystic fibrosis (CF). The second promising compound, AZX1101, is a recombinant beta-lactamase combination sourced from bacteria. This asset is being engineered with a dual aim: to avert nosocomial infections caused by resistant bacterial strains, especially after intravenous beta-lactam antibiotic administration, and to mitigate antibiotic-associated diarrhea (AAD).
Harga Saham
$3.45
Disegerakkan terakhir: 2021-09-21
Modal Pasaran
$4.29M
Perubahan (1 hari)
2.07%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan AzurRx BioPharma, Inc. (AZRX)

Kategori

Healthcare
Pendapatan untuk AzurRx BioPharma, Inc. (AZRX)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini AzurRx BioPharma, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi AzurRx BioPharma, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE